Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

💉 Pfizer, Inc. Goes Bearish | 44, 39 and 34 Coming NextThe PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting star. This candlestick came at a long-term lower high (Dec. 2022 vs Dec. 2021). Trading volume has been decreasing since November 2020. The RSI has moved below 50, now bearish, and is trending down strong. The next and at the same time critical support level is 48.24. If this level breaks, PFE is going to move to 39.91 as a new low with even lower possible, but this level is the main one. Bearish target of 39.91 at 0.618 Fib. retracement level followed by 0.786 or 33.98. There is something going on at Twitter as well... I don't know... Do your own research... Not only about trading but also about your health. Thank you for reading. Namaste.
NYSE:PFEShort
by AlanSantana
1
Pfizer Stock: More Than Just COVID-19 VaccinesYou may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will suffer. While there are certainly challenges facing Pfizer, the conclusion that its stock will suffer is flawed. Despite the company's current predicament, there is a lot to be excited about. Let's explore why Pfizer's stock is becoming increasingly attractive. Over the past five weeks, Pfizer has received a string of positive news. The U.S. Food and Drug Administration (FDA) approved Cibinqo for the treatment of adolescents with atopic dermatitis, marking a significant milestone for the company's growth strategy. Additionally, a late-stage study evaluating the combination of Talzenna and Xtandi to treat metastatic castration-resistant prostate cancer produced positive results, reducing the risk of disease progression or death by 37%. Furthermore, Pfizer announced that regulatory applications for elranatamab had been accepted by the FDA and the European Medicines Agency for the treatment of multiple myeloma. The company expects FDA approval to be granted later this year. In addition, an FDA advisory committee voted to approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, which could open up a major market opportunity for the company. On March 10, the FDA approved Zavzpret for the treatment of migraine. Pfizer acquired the drug as part of its purchase of Biohaven in 2022. The company also announced plans to acquire Seagen for $43 billion, which caused Pfizer's stock to rise significantly. The acquisition will provide Pfizer with four approved cancer drugs and promising antibody-drug conjugates (ADCs) that could generate $10 billion in risk-adjusted revenue by 2030. Despite all of these positive developments, Pfizer's stock remains undervalued by investors. Its price is still nearly 35% below its late 2021 high, trading at just 12 times expected earnings. However, the company's dividend has risen to 4.1%, its highest level since mid-2021. Investors seem to be fixated on the difficulties associated with COVID-19 and its treatment, but Pfizer predicts that even on this front, there is good news to come. The company expects demand for Comirnaty to rise to 98 million doses by 2026 due to the launch of the combination flu vaccine COVID. Additionally, demand for Paxlovid is predicted to grow steadily over the next few years, with the possibility of promoting antiviral therapy in China. In conclusion, while there are certainly challenges facing Pfizer, the outlook for the company's stock is better than many people think. Despite the conventional wisdom that Pfizer's stock will suffer, the company is making significant strides towards achieving its goals. Investors should take note of the recent positive developments and consider investing in this pharmaceutical giant.
NYSE:PFEShort
by FOREXN1
10
3/17 Watchlist + NotesGoing off of yesterday's watchlist and notes, we were expecting bullish movement on SPY and we got it. Very strong close again on SPY leads me to believe we will see a push higher again tomorrow, but I am not entirely sure how much higher. With that being said, I think we are set for a solid friday session. The scanner only had 5 tickers on it today with our main focus being on PFE but I will get into that later. tickers and bias include: KO - 3-1 : Slightly Bullish JNJ - 2-1: Slightly Bullish BABA - 2-1 : Slightly Bearish HD - 2-1-1: Neutral CAT - 2-1: Neutral PFE - 3-1: Bullish PFE is my main focus for tomorrow. It has a similar setup to DOCU from yesterday's list, which is an inside day with a gap to the upside, while having an underlying bullish bias. Looking to break 40.49. If this happens, we target 40.82, 41.13, and 41.26 (Top of daily fair value gap, high of day from the day that created the most recent FVG, and high of last week/bottom of second most recent daily FVG). Overall just going to play it like any other day and watch what SPY and VIX are doing while seeing if any of the inside days from this list breakout. If They break in the direction that SPY is moving then I will consider playing them. I do want to mention that besides PFE, JNJ, and HD, the other setups are not ideal to play, but I want to include them anyways because 1, they were on the scanner, and 2, sometimes these setups surprise me with how well they perform regardless of how they look at first.
NYSE:PFE
by Alanger17
Pfizer 20% BounceTrading plan: 1. Wait until CM_Ultimater_MA_MFT_V2 indicates a reversal of secondary daily trend. This indication will be confirmed by change of the color of MA from red to green. Primary trend is still bearish until confirmed to be bullish. 2. CM_Williams_Vix_Fix at local daily bottom which can be seen as a confirmation of the reversal secondary bearish trend which started on December 29, 2022. 3. WT_LB is below oversold band which is also on daily timeframe is indicating a secondary trend reversal. 4. Resistance should a price ceiling of the bearish channel at $50-$52. Implications: 1. Since CM_Ultimater_MA_MFT_V2 is lagging indicator there is a trade off between confirmation of the trend reversal and return rate of the trade. Therefore it could be prudent to start accumulating the position before we see a confirmation of the trend reversal by this MA. 2. This is post earnings period and Federal hike announcements/meetings have already passed. So volatility should be lower. 3. Of course this trading plan has worked out 100% in the last 8 times (of course there is an element of data mining) but trade should be done cautiously. 4. Stop loss would be if we start consolidating below $41-$40.5 Reckon it does not contract to the rationale I was trying to stick to: - Identify a trend reversal (either primary of secondary on daily and weekly timeframes) - Get into the position after considering different tools of confirmation and setting a stop loss. - Ride the trend until there is a sign of trend reversal (either primary of secondary on daily and weekly timeframes) and try to get it confirmed. - Close the position. Please enjoy and if you have any further insights please share Many thanks to the Community contributors (ChrisMoody and LazyBear). The tools they have assembled are of significant avail to all.
NYSE:PFELong
by Askhat_Kulchiyev
2
PFIZER (PFE) 6M Trading Analisys (TA)6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to $43, heading down to test the 100 days MA signal, at this moment there is a probability for the price to bounce up before continuing its way down to test the 100 MA signal, which is the optimistic approach, but remember "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy". Today this ticker has a Volume of 5.297M with a Market Cap of 246B. This Company PAYS DIVIDENDS TO SHAREHOLDERS Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. Good Luck! Gráfico de 6M, ( PFE ), al 6 de febrero de 2023, las señales en MACD se han estado moviendo constantemente hacia el NE, luego de cruzarse por debajo del histograma en julio de 2012; En julio de 2021, alcanzó su ATH (Mayor Precio Histórico); La señal RSI rebotó sobre 70 y ahora se dirige al SE para probar la señal de 50, luego de rebotar ahi en enero de 2020; El precio ha estado cayendo constantemente desde el ATH, de $60 a $43, bajando para probar la señal de 100 días MA, en este momento existe la probabilidad de que el precio rebote antes de continuar su camino hacia abajo para probar la señal de 100 MA, que es el enfoque optimista, pero recuerda: "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a tener razón nueve de cada diez veces. Descubrí que cuando el mercado está cayendo y compras fondos sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar". Hoy este ticker tiene un Volumen de 5.297M con una Capitalización de Mercado de 246B. Esta Empresa PAGA DIVIDENDOS A LOS ACCIONISTAS Pfizer Inc. es una compañía biofarmacéutica global basada en la investigación. Se dedica al descubrimiento, desarrollo, fabricación, comercialización, venta y distribución de productos biofarmacéuticos en todo el mundo. La firma trabaja en mercados desarrollados y emergentes para promover el bienestar, la prevención, los tratamientos y las curas que desafían las enfermedades más temidas. La empresa fue fundada por Charles Pfizer Sr. y Charles Erhart en 1849 y tiene su sede en Nueva York, NY. ¡Buena suerte! “I believe in analysis and not forecasting.” / "Creo en el análisis y no en el pronóstico". REMEMBER : I am not a financial adviser nor is any content in this article presented as financial advice. The information provided in this blog post and any other posts that I make, and any accompanying material is for informational purposes only. It should not be considered financial or investment advice of any kind. One should consult with a financial or investment professional to determine what may be best for your individual needs. RECUERDE : No soy un asesor financiero y el contenido de este artículo no se presenta como asesoramiento financiero. La información provista en esta publicación de blog y cualquier otra publicación que haga y cualquier material que la acompaña es solo para fines informativos. No debe considerarse asesoramiento financiero o de inversión de ningún tipo. Se debe consultar con un profesional financiero o de inversiones para determinar qué es lo mejor para sus necesidades individuales.
NYSE:PFELong
by rodulfox